1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Hypercholesterolaemia - Pipeline Insight, 2021

Hypercholesterolaemia - Pipeline Insight, 2021

  • June 2021
  • 60 pages
  • ID: 6096842
  • Format: PDF
  • Delve Insight


Table of Contents

“Hypercholesterolaemia - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Hypercholesterolaemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Hypercholesterolaemia Understanding

Hypercholesterolaemia: Overview
Cholesterol is a component (a lipid or fat) that circulates in the bloodstream which the body uses to construct cells and produce certain substances that it needs. In this respect, its presence is both good and necessary. However, hypercholesterolaemia, or an excessive level or amount of cholesterol in the blood, can be harmful because it causes atheromatous plaques to deposit in the arteries (atherosclerosis). Therefore, it predisposes the development of cardiovascular diseases such as heart attacks, strokes or an insufficient blood supply to the limbs.
The need for treatment to reduce cholesterol levels must be individualised to each person and largely depends on the risk of suffering a cardiovascular event. There are several strategies to reduce cholesterol with medicines. For instance, there are drugs that decrease cholesterol production in the liver or which enable the liver to capture or “clean” more cholesterol from the blood. Statins are the treatment of choice and best-known drug therapy against hypercholesterolaemia. Ezetimibe acts by reducing cholesterol absorption in the intestine. Resins act in the intestine by promoting the elimination of bile which has a very high cholesterol content.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Hypercholesterolaemia R&D. The therapies under development are focused on novel approaches for Hypercholesterolaemia.

Hypercholesterolaemia Emerging Drugs Chapters
This segment of the Hypercholesterolaemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hypercholesterolaemia Emerging Drugs
• IBI306: Innovent Biologics
Tafolecimab (IBI306) is a recombinant fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9) developed by Innovent for the treatment of hypercholesterolemia. PCSK9 binds the LDL-R/LDL-C complex and prevents LDL-R dissociation, make it to degrade with LDL-C and thus cannot circulate back to the hepatic cell surface. As the amount of LDL-R expression on the cell surface decreases, the level of LDL-C in the blood will accumulate and increase. Tafolecimab targets PCSK9 and inhibits its binding to LDL-R on the liver cell surface, maintaining the expression of LDL-R on the hepatocyte surface, thereby reducing LDL-C levels.
It is currently in Phase III stage of development for Hypercholesterolaemia and is being developed by Innovent Biologics.
• AK-102: Akeso Biopharma
Ebronucimab (AK102) acts as inhibitors of PCSK9 protein. Ebronucimab (AK102) is being developed for the treatment of acquired and inherited hyperlipidemias, including HoFH, HeFH, and hypercholesterolemias patients with atherosclerotic cardiovascular disease.
It is currently in Phase II stage of development for Hypercholesterolaemia and is being developed by Akeso Biopharma.
Further product details are provided in the report……..

Hypercholesterolaemia: Therapeutic Assessment
This segment of the report provides insights about the different Hypercholesterolaemia drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players working on Hypercholesterolaemia
There are approx. 20+ key companies which are developing the Hypercholesterolaemia. The companies which have their Hypercholesterolaemia drug candidates in the most advanced stage, i.e. Phase III include, Innovent Biologics.
• Phases
This report covers around 20+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Hypercholesterolaemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

• Molecule Type
Products have been categorized under various Molecule types such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hypercholesterolaemia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Hypercholesterolaemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hypercholesterolaemia drugs.

Hypercholesterolaemia Report Insights
• Hypercholesterolaemia Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Hypercholesterolaemia Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:
• How many companies are developing Hypercholesterolaemia drugs?
• How many Hypercholesterolaemia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Hypercholesterolaemia?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hypercholesterolaemia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hypercholesterolaemia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Akeso Biopharma
• LIB Therapeutics
• Innovent Biologics
• Jiangsu HengRui Medicine
• AstraZeneca
• Vaxxinity

Key Products
• AK102
• IBI306
• Lerodalcibep
• SHR-1209
• AZD8233
• Research programme: PCSK 9 inhibitor vaccine

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on